Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Nephrology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1450561

Therapeutic effects of Kangxian Yanshen Formula on patients with chronic kidney disease stages 3-4: a retrospective cohort study

Provisionally accepted
Aojiao Chu Aojiao Chu 1*Wenqian Wei Wenqian Wei 2*Ni Liu Ni Liu 1*Fan Zhang Fan Zhang 1Xianwen Zhang Xianwen Zhang 1*Xueling Li Xueling Li 1*Rong Zheng Rong Zheng 1*Zhifang Ma Zhifang Ma 3*Yi Li Yi Li 1*Shu Rong Shu Rong 2*Zhong Yifei Zhong Yifei 1*
  • 1 Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • 2 Shanghai General Hospital, Shanghai, China
  • 3 Shanghai Fengxian District Traditional Chinese Medicine Hospital, Fengxian, China

The final, formatted version of the article will be published soon.

    Background: This study retrospectively evaluated the actual efficacy of Kangxian Yanshen Formula Chinese medicine on renal function-related indicators in chronic kidney disease (CKD) stage 3-4 patients.In this retrospective cohort study, we collected 212 adult CKD patients with baseline estimated glomerular filtration rate (eGFR) of 15-60 ml/min/1.73 m 2 .All participants received usual care (i.e., Western medications), and participants in the exposure group (n=109) were additionally prescribed Kangxian Yanshen Formula Chinese medicine. The primary outcome was an adjusted hazard risk and 95% confidence interval (95% CI) of a 30% decrease in eGFR at month 36 from baseline.In terms of eGFR, among participants treated with additional Kangxian Yanshen Formula, after adjusting for covariates, there was a 57.1% reduction in the risk of a 30% decline from baseline in eGFR among participants in the Kangxian Yanshen Formula group compared with the Western medicine group (adjusted hazard risk: 0.429; 95% CI 0.269-0.682). In addition, participants in the Kangxian Yanshen Formula group had a significantly higher change in eGFR from baseline to month 12 than those in the western medicine group (3.40±11.62 versus -3.87±8.39; between-group difference Δ5.61 [±2.26 standard deviation] mL/min/1.73 m 2 ; P=0.014). Participants in both groups showed a decreasing trend in eGFR at months 24 and 36.In patients with stage 3-4 CKD, Kangxian Yanshen Formula Chinese medicine therapy may help delay eGFR decline, but high-quality randomized controlled trials are needed to validate the results further.

    Keywords: Kangxian Yanshen Formula, Chronic Kidney Disease, EGFR, Retrospective study, Chinese medicine

    Received: 17 Jun 2024; Accepted: 06 Sep 2024.

    Copyright: © 2024 Chu, Wei, Liu, Zhang, Zhang, Li, Zheng, Ma, Li, Rong and Yifei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Aojiao Chu, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
    Wenqian Wei, Shanghai General Hospital, Shanghai, 201620, China
    Ni Liu, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
    Xianwen Zhang, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
    Xueling Li, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
    Rong Zheng, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
    Zhifang Ma, Shanghai Fengxian District Traditional Chinese Medicine Hospital, Fengxian, China
    Yi Li, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
    Shu Rong, Shanghai General Hospital, Shanghai, 201620, China
    Zhong Yifei, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.